(a) FACS analysis of EPCR expression on circulating and
bone marrow (BM) LSK SLAM cells; representative data are shown for 4 mice.
(b) FACS analysis of EPCR expression on circulating LSK cells
in mice treated with thrombin or PBS; representative data are shown for 4 mice.
(c) Bone marrow EPCR+ LSK cells following thrombin
injection with (n = 4) or without (n = 8)
administration of a PAR1 antagonist; P values, one-way ANOVA
with Tukey’s post-test. (d,e) Soluble EPCR (sEPCR) in bone
marrow fluid 1 hour after thrombin injection, as measured by western blotting
(d) or ELISA (e) in wild-type or
F2r−/− mice; n
= 4. (f) sEPCR ELISA following thrombin stimulation in
vitro in lineage-depleted bone marrow cells; n =
4. (g,h) Bone marrow EPCR+ LSK SLAM cells
(g) and peripheral blood LSK cells (h) in PBS or
thrombin-treated mice, with or without pretreatment with TACE inhibitor for 1
hour before thrombin injection; n = 4; P
values, one-way ANOVA with Tukey’s post-test.